(lp0
(dp1
S'contVal'
p2
NsS'drug2'
p3
S'http://bio2rdf.org/drugbank:DB01137'
p4
sS'drug1'
p5
S'http://bio2rdf.org/drugbank:DB01118'
p6
sS'objectUri'
p7
NsS'evidence'
p8
NsS'ddiPkMechanism'
p9
S'Concomitant blockade of cardiac potassium channels'
p10
sS'whoAnnotated'
p11
NsS'contraindication'
p12
NsS'researchStatementLabel'
p13
NsS'severity'
p14
NsS'label'
p15
NsS'effectConcept'
p16
S'Increased risk of TdP and/or QTc prolongation on ECG'
p17
sS'source'
p18
S'CredibleMeds'
p19
sS'ddiPkEffect'
p20
NsS'homepage'
p21
NsS'pathway'
p22
NsS'ddiType'
p23
NsS'researchStatement'
p24
NsS'dateAnnotated'
p25
NsS'object'
p26
S'AMIODARONE'
p27
sS'evidenceSource'
p28
NsS'evidenceStatement'
p29
NsS'precipUri'
p30
NsS'certainty'
p31
NsS'uri'
p32
NsS'evidenceType'
p33
NsS'numericVal'
p34
NsS'precaution'
p35
NsS'precipitant'
p36
S'LEVOFLOXACIN'
p37
sa(dp38
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01155'
p39
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p40
sg7
Nsg8
Nsg9
S'Concomitant blockade of cardiac potassium channels'
p41
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased risk of TdP and/or QTc prolongation on ECG'
p42
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'AMIODARONE'
p43
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GEMIFLOXACIN'
p44
sa(dp45
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00218'
p46
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p47
sg7
Nsg8
Nsg9
S'Concomitant blockade of cardiac potassium channels'
p48
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased risk of TdP and/or QTc prolongation on ECG'
p49
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'AMIODARONE'
p50
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MOXIFLOXACIN'
p51
sa(dp52
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01165'
p53
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p54
sg7
Nsg8
Nsg9
S'Concomitant blockade of cardiac potassium channels'
p55
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased risk of TdP and/or QTc prolongation on ECG'
p56
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'AMIODARONE'
p57
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'OFLOXACIN'
p58
sa(dp59
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00537'
p60
sg5
S'http://bio2rdf.org/drugbank:DB01118'
p61
sg7
Nsg8
Nsg9
S'Concomitant blockade of cardiac potassium channels'
p62
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased risk of TdP and/or QTc prolongation on ECG'
p63
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'AMIODARONE'
p64
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CIPROFLOXACIN'
p65
sa(dp66
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p67
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p68
sg7
Nsg8
Nsg9
S'Inhibition of carbamazepine metabolism by CYP3A4'
p69
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased carbamazepine concentrations and risk of carbamazepine toxicity'
p70
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p71
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN'
p72
sa(dp73
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p74
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p75
sg7
Nsg8
Nsg9
S'Inhibition of carbamazepine metabolism by CYP3A4'
p76
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased carbamazepine concentrations and risk of carbamazepine toxicity'
p77
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p78
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN'
p79
sa(dp80
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00976'
p81
sg5
S'http://bio2rdf.org/drugbank:DB00564'
p82
sg7
Nsg8
Nsg9
S'Inhibition of carbamazepine metabolism by CYP3A4'
p83
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased carbamazepine concentrations and risk of carbamazepine toxicity'
p84
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'CARBAMAZEPINE'
p85
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TELITHROMYCIN'
p86
sa(dp87
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00338'
p88
sg5
S'http://bio2rdf.org/drugbank:DB00758'
p89
sg7
Nsg8
Nsg9
S'Inhibition of clopidogrel (prodrug) metabolism to active metabolite by CYP2C19'
p90
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Decreased concentrations of clopidogrel active metabolite and decreased antiplatelet effects'
p91
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'CLOPIDOGREL'
p92
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'OMEPRAZOLE'
p93
sa(dp94
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01211'
p95
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p96
sg7
Nsg8
Nsg9
S'Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin'
p97
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased digoxin concentrations and risk of digoxin toxicity'
p98
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'DIGOXIN '
p99
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CLARITHROMYCIN  '
p100
sa(dp101
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00199'
p102
sg5
S'http://bio2rdf.org/drugbank:DB00390'
p103
sg7
Nsg8
Nsg9
S'Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin'
p104
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased digoxin concentrations and risk of digoxin toxicity'
p105
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'DIGOXIN'
p106
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ERYTHROMYCIN   '
p107
sa(dp108
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p109
sg5
S'http://bio2rdf.org/drugbank:DB00391'
p110
sg7
Nsg8
Nsg9
S'Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin'
p111
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased digoxin concentrations and risk of digoxin toxicity'
p112
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'DIGOXIN'
p113
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ITRACONAZOLE    '
p114
sa(dp115
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p116
sg5
S'http://bio2rdf.org/drugbank:DB00392'
p117
sg7
Nsg8
Nsg9
S'Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin'
p118
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased digoxin concentrations and risk of digoxin toxicity'
p119
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'DIGOXIN'
p120
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KETOCONAZOLE    '
p121
sa(dp122
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01263'
p123
sg5
S'http://bio2rdf.org/drugbank:DB00393'
p124
sg7
Nsg8
Nsg9
S'Inhibition of digoxin transport by P-glycoprotein resulting in reduced renal and nonrenal elimination of digoxin'
p125
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased digoxin concentrations and risk of digoxin toxicity'
p126
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'DIGOXIN'
p127
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POSACONAZOLE    '
p128
sa(dp129
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p130
sg5
S'http://bio2rdf.org/drugbank:DB00641'
p131
sg7
Nsg8
Nsg9
S'Inhibition of metabolism of simvastatin/ lovastatin by CYP3A4'
p132
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p133
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'SIMVASTATIN'
p134
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIODARONE'
p135
sa(dp136
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p137
sg5
S'http://bio2rdf.org/drugbank:DB01076'
p138
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p139
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p140
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ATORVASTATIN CALCIUM'
p141
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ITRACONAZOLE    '
p142
sa(dp143
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p144
sg5
S'http://bio2rdf.org/drugbank:DB01077'
p145
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p146
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p147
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ATORVASTATIN CALCIUM'
p148
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KETOCONAZOLE'
p149
sa(dp150
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01263'
p151
sg5
S'http://bio2rdf.org/drugbank:DB01078'
p152
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p153
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p154
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ATORVASTATIN CALCIUM'
p155
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POSACONAZOLE'
p156
sa(dp157
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p158
sg5
S'http://bio2rdf.org/drugbank:DB01079'
p159
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p160
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p161
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ATORVASTATIN CALCIUM'
p162
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p163
sa(dp164
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p165
sg5
S'http://bio2rdf.org/drugbank:DB01080'
p166
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p167
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p168
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ATORVASTATIN CALCIUM'
p169
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p170
sa(dp171
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p172
sg5
S'http://bio2rdf.org/drugbank:DB01095'
p173
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p174
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p175
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'FLUVASTATIN'
p176
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ITRACONAZOLE'
p177
sa(dp178
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p179
sg5
S'http://bio2rdf.org/drugbank:DB01095'
p180
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p181
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p182
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'FLUVASTATIN'
p183
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KETOCONAZOLE'
p184
sa(dp185
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01263'
p186
sg5
S'http://bio2rdf.org/drugbank:DB01095'
p187
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p188
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p189
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'FLUVASTATIN'
p190
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POSACONAZOLE'
p191
sa(dp192
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p193
sg5
S'http://bio2rdf.org/drugbank:DB01095'
p194
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p195
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p196
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'FLUVASTATIN'
p197
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p198
sa(dp199
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p200
sg5
S'http://bio2rdf.org/drugbank:DB01095'
p201
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p202
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p203
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'FLUVASTATIN'
p204
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p205
sa(dp206
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p207
sg5
S'http://bio2rdf.org/drugbank:DB00227'
p208
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p209
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p210
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'LOVASTATIN'
p211
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ITRACONAZOLE'
p212
sa(dp213
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p214
sg5
S'http://bio2rdf.org/drugbank:DB00227'
p215
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p216
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p217
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'LOVASTATIN'
p218
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KETOCONAZOLE'
p219
sa(dp220
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01263'
p221
sg5
S'http://bio2rdf.org/drugbank:DB00227'
p222
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p223
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p224
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'LOVASTATIN'
p225
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POSACONAZOLE'
p226
sa(dp227
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p228
sg5
S'http://bio2rdf.org/drugbank:DB00227'
p229
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p230
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p231
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'LOVASTATIN'
p232
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p233
sa(dp234
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p235
sg5
S'http://bio2rdf.org/drugbank:DB00227'
p236
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p237
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p238
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'LOVASTATIN'
p239
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p240
sa(dp241
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p242
sg5
S'http://bio2rdf.org/drugbank:DB00175'
p243
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p244
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p245
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'PRAVASTATIN'
p246
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ITRACONAZOLE'
p247
sa(dp248
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p249
sg5
S'http://bio2rdf.org/drugbank:DB00175'
p250
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p251
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p252
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'PRAVASTATIN'
p253
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KETOCONAZOLE'
p254
sa(dp255
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01263'
p256
sg5
S'http://bio2rdf.org/drugbank:DB00175'
p257
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p258
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p259
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'PRAVASTATIN'
p260
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POSACONAZOLE'
p261
sa(dp262
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p263
sg5
S'http://bio2rdf.org/drugbank:DB00175'
p264
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p265
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p266
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'PRAVASTATIN'
p267
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p268
sa(dp269
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p270
sg5
S'http://bio2rdf.org/drugbank:DB00175'
p271
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p272
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p273
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'PRAVASTATIN'
p274
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p275
sa(dp276
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p277
sg5
S'http://bio2rdf.org/drugbank:DB01098'
p278
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p279
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p280
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ROSUVASTATIN'
p281
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ITRACONAZOLE'
p282
sa(dp283
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p284
sg5
S'http://bio2rdf.org/drugbank:DB01098'
p285
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p286
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p287
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ROSUVASTATIN'
p288
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KETOCONAZOLE'
p289
sa(dp290
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01263'
p291
sg5
S'http://bio2rdf.org/drugbank:DB01098'
p292
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p293
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p294
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ROSUVASTATIN'
p295
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POSACONAZOLE'
p296
sa(dp297
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p298
sg5
S'http://bio2rdf.org/drugbank:DB01098'
p299
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p300
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p301
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ROSUVASTATIN'
p302
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p303
sa(dp304
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p305
sg5
S'http://bio2rdf.org/drugbank:DB01098'
p306
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p307
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p308
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'ROSUVASTATIN'
p309
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p310
sa(dp311
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01167'
p312
sg5
S'http://bio2rdf.org/drugbank:DB00641'
p313
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p314
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p315
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'SIMVASTATIN'
p316
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ITRACONAZOLE'
p317
sa(dp318
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01026'
p319
sg5
S'http://bio2rdf.org/drugbank:DB00641'
p320
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p321
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p322
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'SIMVASTATIN'
p323
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KETOCONAZOLE'
p324
sa(dp325
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01263'
p326
sg5
S'http://bio2rdf.org/drugbank:DB00641'
p327
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p328
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p329
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'SIMVASTATIN'
p330
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'POSACONAZOLE'
p331
sa(dp332
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p333
sg5
S'http://bio2rdf.org/drugbank:DB00641'
p334
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p335
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p336
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'SIMVASTATIN'
p337
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p338
sa(dp339
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p340
sg5
S'http://bio2rdf.org/drugbank:DB00641'
p341
sg7
Nsg8
Nsg9
S'Inhibition of simvastatin/ lovastatin metabolism by CYP3A4'
p342
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased simvastatin/ lovastatin concentrations and risk of myopathy/ rhabdomyolysis'
p343
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'SIMVASTATIN'
p344
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p345
sa(dp346
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01156'
p347
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p348
sg7
Nsg8
Nsg9
S'Inhibition of activation of tamoxifen (prodrug) to its major active metabolite by CYP2D6'
p349
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Decreased clinical effectiveness of tamoxifen (decreased disease-free survival); people with \xef\xbf\xbdnormal\xef\xbf\xbd CYP2D6 activity (extensive metabolizers) would be at risk of this interaction'
p350
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'TAMOXIFEN'
p351
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'BUPROPION'
p352
sa(dp353
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00476'
p354
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p355
sg7
Nsg8
Nsg9
S'Inhibition of activation of tamoxifen (prodrug) to its major active metabolite by CYP2D6'
p356
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Decreased clinical effectiveness of tamoxifen (decreased disease-free survival); people with \xef\xbf\xbdnormal\xef\xbf\xbd CYP2D6 activity (extensive metabolizers) would be at risk of this interaction'
p357
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'TAMOXIFEN'
p358
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DULOXETINE'
p359
sa(dp360
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00472'
p361
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p362
sg7
Nsg8
Nsg9
S'Inhibition of activation of tamoxifen (prodrug) to its major active metabolite by CYP2D6'
p363
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Decreased clinical effectiveness of tamoxifen (decreased disease-free survival); people with \xef\xbf\xbdnormal\xef\xbf\xbd CYP2D6 activity (extensive metabolizers) would be at risk of this interaction'
p364
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'TAMOXIFEN'
p365
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUOXETINE'
p366
sa(dp367
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00715'
p368
sg5
S'http://bio2rdf.org/drugbank:DB00675'
p369
sg7
Nsg8
Nsg9
S'Inhibition of activation of tamoxifen (prodrug) to its major active metabolite by CYP2D6'
p370
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Decreased clinical effectiveness of tamoxifen (decreased disease-free survival); people with \xef\xbf\xbdnormal\xef\xbf\xbd CYP2D6 activity (extensive metabolizers) would be at risk of this interaction'
p371
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'TAMOXIFEN'
p372
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PAROXETINE'
p373
sa(dp374
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01118'
p375
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p376
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C9'
p377
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p378
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p379
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'AMIODARONE'
p380
sa(dp381
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00196'
p382
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p383
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C9'
p384
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p385
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p386
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUCONAZOLE'
p387
sa(dp388
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01110'
p389
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p390
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C10'
p391
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p392
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p393
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MICONAZOLE'
p394
sa(dp395
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00582'
p396
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p397
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C11'
p398
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p399
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p400
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'VORICONAZOLE'
p401
sa(dp402
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00564'
p403
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p404
sg7
Nsg8
Nsg9
S'Induction of warfarin metabolism'
p405
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Decreased warfarin concentrations and warfarin effects'
p406
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p407
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CARBAMAZEPINE'
p408
sa(dp409
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01241'
p410
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p411
sg7
Nsg8
Nsg9
S'Not established'
p412
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin effect and bleeding risk'
p413
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p414
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'GEMFIBROZIL'
p415
sa(dp416
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01039'
p417
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p418
sg7
Nsg8
Nsg9
S'Not established'
p419
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin effect and bleeding risk'
p420
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p421
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FENOFIBRATE'
p422
sa(dp423
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00482'
p424
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p425
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p426
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p427
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p428
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'CELECOXIB'
p429
sa(dp430
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00586'
p431
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p432
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p433
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p434
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p435
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DICLOFENAC'
p436
sa(dp437
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00861'
p438
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p439
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p440
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p441
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p442
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'DIFLUNISAL'
p443
sa(dp444
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00749'
p445
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p446
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p447
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p448
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p449
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ETODOLAC'
p450
sa(dp451
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00573'
p452
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p453
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p454
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p455
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p456
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FENOPROFEN'
p457
sa(dp458
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00712'
p459
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p460
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p461
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p462
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p463
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLURBIPROFEN'
p464
sa(dp465
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01050'
p466
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p467
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p468
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p469
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p470
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'IBUPROFEN'
p471
sa(dp472
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00328'
p473
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p474
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p475
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p476
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p477
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'INDOMETHACIN'
p478
sa(dp479
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01009'
p480
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p481
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p482
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p483
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p484
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KETOPROFEN'
p485
sa(dp486
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00465'
p487
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p488
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p489
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p490
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p491
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'KETOROLAC'
p492
sa(dp493
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00784'
p494
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p495
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p496
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p497
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p498
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MEFENAMIC ACID'
p499
sa(dp500
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00814'
p501
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p502
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p503
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p504
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p505
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'MELOXICAM'
p506
sa(dp507
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00461'
p508
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p509
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p510
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p511
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p512
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NABUMETONE'
p513
sa(dp514
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00788'
p515
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p516
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p517
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p518
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p519
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'NAPROXEN'
p520
sa(dp521
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00991'
p522
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p523
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p524
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p525
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p526
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'OXAPROZIN'
p527
sa(dp528
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00554'
p529
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p530
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p531
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p532
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p533
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'PIROXICAM'
p534
sa(dp535
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00605'
p536
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p537
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p538
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p539
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p540
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULINDAC'
p541
sa(dp542
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00500'
p543
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p544
sg7
Nsg8
Nsg9
S'\xef\xbf\xbdAntiplatelet effects and GI erosion associated with NSAIDs and the anticoagulant effect of warfarin. \xef\xbf\xbdSome individual NSAIDs may also alter the pharmacokinetics of warfarin'
p545
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Additive risk of bleeding'
p546
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p547
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'TOLMETIN'
p548
sa(dp549
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01095'
p550
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p551
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C9 is proposed'
p552
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p553
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p554
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'FLUVASTATIN'
p555
sa(dp556
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00227'
p557
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p558
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C9 is proposed'
p559
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p560
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p561
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LOVASTATIN'
p562
sa(dp563
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01098'
p564
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p565
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C9 is proposed'
p566
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p567
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p568
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'ROSUVASTATIN'
p569
sa(dp570
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00641'
p571
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p572
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C9 is proposed'
p573
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p574
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p575
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SIMVASTATIN'
p576
sa(dp577
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01015'
p578
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p579
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C9'
p580
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p581
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p582
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'SULFAMETHOXAZOLE/TRIMETHOPRIM  '
p583
sa(dp584
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00916'
p585
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p586
sg7
Nsg8
Nsg9
S'Inhibition of warfarin metabolism by CYP2C9'
p587
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased warfarin concentrations and bleeding risk'
p588
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p589
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'METRONIDAZOLE'
p590
sa(dp591
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00451'
p592
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p593
sg7
Nsg8
Nsg9
S'An accelerated depletion of vitamin K-dependent clotting factors as a result of thyroid hormone administration has been proposed'
p594
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased bleeding risk'
p595
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p596
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LEVOTHYROXINE'
p597
sa(dp598
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB00279'
p599
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p600
sg7
Nsg8
Nsg9
S'An accelerated depletion of vitamin K-dependent clotting factors as a result of thyroid hormone administration has been proposed'
p601
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased bleeding risk'
p602
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p603
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LIOTHYRONINE'
p604
sa(dp605
g2
Nsg3
S'http://bio2rdf.org/drugbank:DB01583'
p606
sg5
S'http://bio2rdf.org/drugbank:DB00682'
p607
sg7
Nsg8
Nsg9
S'An accelerated depletion of vitamin K-dependent clotting factors as a result of thyroid hormone administration has been proposed'
p608
sg11
Nsg12
Nsg13
Nsg14
Nsg15
Nsg16
S'Increased bleeding risk'
p609
sg18
g19
sg20
Nsg21
Nsg22
Nsg23
Nsg24
Nsg25
Nsg26
S'WARFARIN'
p610
sg28
Nsg29
Nsg30
Nsg31
Nsg32
Nsg33
Nsg34
Nsg35
Nsg36
S'LIOTRIX '
p611
sa.